Ascentage Pharma Group International vs Arcutis Biotherapeutics
AAPG and ARQT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and ARQT compare
Arcutis Biotherapeutics grew revenue faster over the last twelve months (60.0% versus −41.5% for Ascentage Pharma Group International).
Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 5.9% compared with −216% at Ascentage Pharma Group International.
Arcutis Biotherapeutics scores higher on the StockData Score (11 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | ARQT |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.6B |
| Share price | $14.62 | $28.26 |
| Change, 1 year | −55.6% | 20.5% |
| Change, 5 years | – | 55.4% |
| Beta (5Y) | 0.79 | 0.92 |
| Employees | 767 | 354 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 4 (better) |
| Performance score | 1 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 128× |
| P/S | – | 7.0× |
| P/B | – | 14.6× |
| EV/EBITDA | – | 96.7× |
| P/FCF | – | 59.5× |
| FCF yield | – | 1.7% |
| Fair value | – | $6.04 |
| Margin of safety | – | −368% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 60.0% (better) |
| Profitability | ||
| Gross margin | 91.5% (better) | 91.2% |
| Operating margin | – | 6.9% |
| Net margin | −216% | 5.9% (better) |
| FCF margin | −209% | 11.7% (better) |
| Return on equity | −156% | 14.9% (better) |
| Return on invested capital | – | 32.9% |
| Financial health | ||
| Debt / equity | 1.50 | 0.45 (better) |
| Net debt / EBITDA | – | −4.27 |
| Interest coverage | – | 2.6× |
| Current ratio | 1.79 | 2.92 (better) |
| Altman Z-score | – | 6.54 |
| Piotroski F-score | – | 4 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 0.00% | 105% |
| Held by insiders | 13.0% | 9.3% |
| Insider net buying, 12 months | – | −$11.1M |
| Short interest, % of float | – | 15.9% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- ARQT stock overview
- ARQT income statement
- ARQT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.